4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988 · 4D Molecular Therapeutics
Recruitment statusRecorded edit
− Previous value
Recruiting
+ Updated value
Active not recruiting
FDMT
4D Molecular Therapeutics
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
4Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| 4D-710 in Adult Patients With Cystic FibrosisNCT05248230 | 4D Molecular Therapeutics | Phase 2 | Recruiting | 2027-06Estimated |
| 4D-150 in Patients With Diabetic Macular EdemaNCT05930561 | 4D Molecular Therapeutics | Phase 2 | Active not recruiting | 2029-02-28Estimated |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988 | 4D Molecular Therapeutics | Phase 3 | Active not recruiting | 2027-06Estimated |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT07064759 | 4D Molecular Therapeutics | Phase 3 | Recruiting | 2028-11Estimated |
Latest recorded trial changes
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230 · 4D Molecular Therapeutics
Primary completion dateRecorded edit
− Previous value
2026-12
+ Updated value
2027-06
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230 · 4D Molecular Therapeutics
Enrollment · participant countRecorded edit
− Previous value
count: 40; type: ESTIMATED
+ Updated value
count: 30; type: ESTIMATED
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759 · 4D Molecular Therapeutics
Enrollment · participant countRecorded edit
− Previous value
count: 400; type: ESTIMATED
+ Updated value
count: 480; type: ESTIMATED
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988 · 4D Molecular Therapeutics
Enrollment · participant countRecorded edit
− Previous value
count: 400; type: ESTIMATED
+ Updated value
count: 480; type: ESTIMATED
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230 · 4D Molecular Therapeutics
PhaseRecorded edit
− Previous value
PHASE1, PHASE2
+ Updated value
PHASE2
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759 · 4D Molecular Therapeutics
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: Mean change from baseline in BCVA ETDRS letter score at Week 52
+ Updated value
measure: Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52
Check registry source · The saved outcome text may be shortened. Check the source for full wording.